Why Prometheus will have little effect on Myriad
26 March 2012
|
Karen Bolipata, New York
The US Supreme Court today granted cert in Association for Molecular Pathology v Myriad Genetics, vacating the judgment and remanding the case to the Federal Circuit
This is in light of last week''s ruling in Mayo v Prometheus, in which the Court found the diagnostic method patents owned by Prometheus invalid.
Lawyers told Managing IP it''s unlikely Prometheus would lead the Federal Circuit to change its decision.
"One, Myriad isn''t claiming a product or law of nature in the first place – it claims...
Only subscribers have complete access to Managing IP,
log in or
subscribe now.
Alternatively take a
free trial, giving you seven days access to Managing IP and regular newsletters for the international IP community, and US and Canadian practitioners specifically.
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial